The FDA is listening - Raise YOUR Voice!
Come back TOMORROW to Join the Meeting!
At STAAR, we are dedicated to improving the lives of people diagnosed with low-grade serous ovarian cancer.
One powerful way we can achieve this is by ensuring that the FDA—the federal agency responsible for evaluating drugs in the United States—hears our stories about living with this disease and undergoing treatment By incorporating our voices, the FDA can make more informed decisions that directly impact our lives. Patient-Focused Drug Development MeetingWhat is a patient-focused drug development (PFDD) meeting?
One of the FDA’s missions is to protect and promote public health by evaluating the safety and effectiveness of new drugs, biologics, and devices. The FDA does not develop drugs nor conduct clinical trials. FDA does, however, play a constructive role in guiding, helping, or evaluating at some stages of the pre-clinical, translational, and clinical development work. On October 13, 2023, from 10 am to 3 pm ET, STAAR is hosting a live and interactive virtual meeting to give the LGSOC community an opportunity to tell our stories to the FDA . In preparation for the meeting, we have worked with partners Cure our Ovarian Cancer and World Ovarian Cancer Coalition, and collected patient stories and comments and recorded some on video to be shared at the event. Other stories will be shared live at the webinar. Please join #myLGSOCstory by sharing your experience with LGSOC now. |
Three Ways YOU Can Help:
Spread the WordShare this page with everyone you know! The more participation we get, the better informed the FDA is on providing us with the treatments we need! Spread the word via email, social media, tell your friends, invite your healthcare providers.
© STAAR Ovarian Cancer Foundation. All rights reserved. Privacy Policy Support Us
|